Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 229 (6%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3283 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (13%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2022-11-27 | 2022-12-23 | 175892 |
| APO-PRAVASTATIN | 20MG | TABLET | Resolved | 2022-12-23 | 2023-01-20 | 179459 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2024-02-02 | 2024-04-12 | 218397 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-02-02 | 2024-04-05 | 218400 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2024-03-22 | 2024-04-12 | 223064 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-03-27 | 2024-04-05 | 223549 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-04-26 | 2024-06-28 | 226336 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-05-31 | 2024-06-28 | 229413 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-07-12 | 2024-07-26 | 232826 |
| APO-PRAZO | 1MG | TABLET | Resolved | 2018-01-18 | 2018-06-12 | 36441 |
| APO-PRAZO | 1MG | TABLET | Resolved | 2019-02-24 | 2019-04-08 | 76732 |
| APO-PRAZO | 1MG | TABLET | Resolved | 2020-04-13 | 2020-06-22 | 111946 |
| APO-PRAZO | 1MG | TABLET | Resolved | 2023-01-20 | 2025-03-12 | 181967 |
| APO-PRAZO | 2MG | TABLET | Resolved | 2017-11-28 | 2018-01-29 | 31019 |
| APO-PRAZO | 2MG | TABLET | Resolved | 2020-09-02 | 2020-10-16 | 123574 |
| APO-PRAZO | 2MG | TABLET | Resolved | 2023-04-06 | 2025-03-12 | 188943 |
| APO-PRAZO | 5MG | TABLET | Resolved | 2018-03-13 | 2018-06-12 | 42700 |
| APO-PRAZO | 5MG | TABLET | Resolved | 2018-11-21 | 2019-03-26 | 67409 |
| APO-PRAZO | 5MG | TABLET | Resolved | 2020-04-15 | 2020-06-22 | 112192 |
| APO-PRAZO | 5MG | TABLET | Resolved | 2020-08-12 | 2020-10-19 | 122074 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |